Pipeline | ANAVEX Our pipeline includes one drug candidate and several compounds in different stages of pre-clinical study. Our proprietary SIGMACEPTOR™ Discovery Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. Anavex Life Sciences Corp. Common Stock (AVXL) Analyst ... AVXL Anavex Life Sciences Corp. Common Stock. Data is currently not available. $3.91. UNCH. DATA AS OF Jun 04, 2020 7:49 PM ET - AFTER HOURS. $3.91. 0.09 (2.36%) CLOSED AT …
Anavex Life Sciences Corp. AVXL 4.02 0.12 (3.11%). NASDAQ Updated Jun 8, 2020 9:58 PM
View Anavex Life Sciences Corp AVXL investment & stock information. Get the latest Anavex Life Sciences Corp AVXL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. anavex life sciences corp (avxl): * anavex life sciences reports fiscal 2020 second quarter financial results and provides business updates. * q2 loss per share $0.12. * Q2 LOSS PER SHARE $0.12. * Q2 EARNINGS PER SHARE ESTIMATE $-0.16 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage: Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer s disease, Parkinson s disease, Rett syndrome and other central nervous system diseases, today announced that it has received a No Objection Letter from Health Canada as well as Clinical AVXL Stock Message Board for Investors. Anavex Life Sciences Corp. Stock Price, News and Company Updates. Message Board Total Posts: 1037 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) GlobeNewswire Inc. - 2/24/2020 7:00:10 AM Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/20/2020 4:32:14 PM
The latest messages and market ideas from Anavex Life Sciences Corp. (@Anavex) on Stocktwits. Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of Alzheimer’s and other neurological diseases and cancer.
AVXL Stock Message Board for Investors. Anavex Life Sciences Corp. Stock Price, News and Company Updates. Message Board Total Posts: 1037
Follow Us! StockTwits Twitter · ETF Daily News. Toggle navigation AVXL · ANAVEX LIFE SCIENCES CORP, 0.00%. BRT · BRT Apartments Corp, 0.00%.
News | ANAVEX Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s Disease. June 4, 2020. May 21 2020. Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX… Events | ANAVEX Anavex Life Sciences will present at AAIC 2019 in Los Angeles, CA oral presentation, titled, 'Exploring gut microbiota as a source of potential biomarkers: Initial results from the ANAVEX®2-73 Alzheimer’s disease clinical study' July 17th 2019, 8:45 AM PT/11:45 AM ET
Anavex Life Sciences Corp. (AVXL) Latest Stock News ...
Events | ANAVEX Anavex Life Sciences will present at AAIC 2019 in Los Angeles, CA oral presentation, titled, 'Exploring gut microbiota as a source of potential biomarkers: Initial results from the ANAVEX®2-73 Alzheimer’s disease clinical study' July 17th 2019, 8:45 AM PT/11:45 AM ET Anavex Life Sciences Corp (AVXL): This board, Stocktwits ... Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B) GlobeNewswire Inc. - 5/21/2020 7:00:10 AM Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2020 4:41:44 PM Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business Updates GlobeNewswire Inc. - 5/7/2020 7:00:10 AM Anavex Life Sciences (NasdaqCM:AVXL) - Simply Wall St